Il Dong Pharmaceutical Co Ltd Total Assets
Il Dong Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Il Dong Pharmaceutical Co Ltd (249420) holds total assets worth ₩573.88 Billion KRW (≈ $388.91 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 249420 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Il Dong Pharmaceutical Co Ltd (2016–2024)
Total assets of Il Dong Pharmaceutical Co Ltd from 2016 to 2024. This chart illustrates how Il Dong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 249420 stock price and chart for real-time trading data and today's change.
Il Dong Pharmaceutical Co Ltd - Asset Composition Analysis
Il Dong Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Il Dong Pharmaceutical Co Ltd total assets breakdown as of December 2024. Il Dong Pharmaceutical Co Ltd's total assets of ₩573.88 Billion consist of 41.9% current assets and 58.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 12.3% |
| Accounts Receivable | ₩44.44 Billion | 7.5% |
| Inventory | ₩87.94 Billion | 14.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩28.83 Billion | 4.9% |
| Goodwill | ₩5.53 Billion | 0.9% |
Asset Composition Trend (2016–2024)
This chart illustrates how Il Dong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Il Dong Pharmaceutical Co Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Il Dong Pharmaceutical Co Ltd's current assets represent 41.9% of total assets in 2024, an increase from 39.7% in 2016.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2024, up from 3.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 13.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 14.9% of total assets.
Il Dong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Il Dong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Il Dong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.91 | 0.90 | 1.26 |
| Quick Ratio | 0.50 | 0.59 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-21.04 Billion | ₩-28.07 Billion | ₩48.23 Billion |
Il Dong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Il Dong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.90 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.6% |
| Total Assets | ₩589.04 Billion |
| Market Capitalization | $260.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Il Dong Pharmaceutical Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Il Dong Pharmaceutical Co Ltd's assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Il Dong Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total assets of Il Dong Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩589.04 Billion ≈ $399.19 Million |
-3.63% |
| 2023-12-31 | ₩611.26 Billion ≈ $414.24 Million |
-6.79% |
| 2022-12-31 | ₩655.81 Billion ≈ $444.43 Million |
-7.50% |
| 2021-12-31 | ₩708.97 Billion ≈ $480.46 Million |
+17.13% |
| 2020-12-31 | ₩605.28 Billion ≈ $410.19 Million |
-1.22% |
| 2019-12-31 | ₩612.72 Billion ≈ $415.23 Million |
+8.51% |
| 2018-12-31 | ₩564.67 Billion ≈ $382.67 Million |
+0.01% |
| 2017-12-31 | ₩564.63 Billion ≈ $382.64 Million |
+2.59% |
| 2016-12-31 | ₩550.35 Billion ≈ $372.97 Million |
-- |
About Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more